A Phase 3 interventional study of Lenalidomide and Dexamethasone in Lymphoma and Multiple Myeloma, sponsored by Bristol-Myers Squibb. Completed at 216 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-01.
Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing dexamethasone in Lymphoma — 4 open to participants now, 8 under way, 1 of them phase 3. Dexamethasone · Lymphoma.
Among the 44 studies testing dexamethasone in Lymphoma, this one is the 4th largest by enrollment of the 42 interventional ones that give a count, is the only one that started in 2011, is one of 7 in phase 3, and was the 33rd registered.
3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.
Browse Lymphoma studies →4 of the 44 studies testing dexamethasone in Lymphoma are open now, in 2 countries. Recruiting first, the newest first:
M.D. Anderson Cancer Center · Sites in United States
Ages 12–30
Fondazione Italiana Linfomi - ETS · Sites in Italy
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
Hematology department of the 920th hospital
Ages 18–65
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 32 · Phase 3 8
First in 1990; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 646 is above the median of 43 across 2,320 interventional studies indexed under Lymphoma.
Median enrollment 48 across the 42 interventional studies. Of the 30 that completed or were terminated, 12 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 44 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
42 studies in Lymphoma by Bristol-Myers Squibb: 2 open now, 5 under way, 1 of them phase 3. Of 36 finished, 17 (47%) have results posted.
Among the 42 studies in Lymphoma by Bristol-Myers Squibb, this one is the 2nd largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2011, is one of 5 in phase 3, and was the 10th registered.
Bristol-Myers Squibb’s Lymphoma studies by the year they started, since 2006.
2 of the studies testing dexamethasone in Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02436707Canadian Cancer Trials GroupNovel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | 2026-12-31 |
| NCT04915248Fondazione Italiana Linfomi - ETSStudy to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. | 2027-07-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies testing dexamethasone in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 42 in Lymphoma:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression free survival (PFS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Prior treatment with Lenalidomide permitted if:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Lenalidomide · Drug: Dexamethasone
Drug: Lenalidomide · Drug: Dexamethasone (Oral) · Drug: Dexamethasone (IV) · Biological: Elotuzumab (BMS-901608; HuLuc63)
Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Also known as: Revlimid®
Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®
On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug. On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®
On weeks without Elotuzumab dosing: Not Applicable (N/A) On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug
Also known as: Decadron®, Dexamethasone Intensol®, Dexpak®, Taperpak®
Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1\&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
Median Progression Free Survival (PFS)
Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication.
Time frame: From randomization up to 326 events (up to approximately 38 months)
Objective Response Rate (ORR)
Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR \[sCR\], complete response \[CR\], very good partial response \[VGPR\], and partial response \[PR\]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks.
Time frame: From randomization up to approximately 38 months
Median Overall Survival (OS)
Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact ("last known alive date"). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)
Time frame: Randomization to the date of death from any cause (up to approximately 9 years)
Change From Baseline of Mean Score Pain Severity (BPI-SF)
The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.
Time frame: From baseline up to approximately 38 months
Change From Baseline of Mean Score Pain Interference (BPI-SF)
The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.
Time frame: From baseline up to approximately 38 months
| Milestone | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Started | 321 | 325 |
| Completed | 319 | 316 |
| Not completed | 2 | 9 |
| Withdrew: Participant no longer meets study criteria | 1 | 1 |
| Withdrew: Participant withdrew consent | 1 | 7 |
| Withdrew: Adverse event unrelated to study drug | 0 | 1 |
| Milestone | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Started | 318 | 317 |
| Completed | 0 | 0 |
| Not completed | 318 | 317 |
| Withdrew: Disease progression | 185 | 185 |
| Withdrew: Study drug toxicity | 39 | 45 |
| Withdrew: Adverse event unrelated to study drug | 31 | 37 |
| Withdrew: Participants request to discontinue study treatment | 28 | 18 |
| Withdrew: Administrative reason by sponsor | 13 | 4 |
| Withdrew: Other reasons | 14 | 14 |
| Withdrew: Participant withdrew consent | 6 | 11 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Participant no longer meets study criteria | 1 | 1 |
| Withdrew: Poor/non-compliance | 0 | 1 |
Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication.
| Months | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Median Progression Free Survival (PFS) | 19.35 (16.62 to 22.18) | 14.85 (12.09 to 17.22) |
The time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication based on Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 06-Jul-2018)
| Months | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Median Progression Free Survival (PFS) - Extended Collection | 19.42 (16.62 to 22.31) | 14.92 (12.25 to 17.31) |
Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR \[sCR\], complete response \[CR\], very good partial response \[VGPR\], and partial response \[PR\]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (\> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks.
| Percentage of participants | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Objective Response Rate (ORR) | 78.5 (73.6 to 82.9) | 65.5 (60.1 to 70.7) |
Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact ("last known alive date"). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)
| Months | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Median Overall Survival (OS) | 48.30 (40.34 to 51.94) | 39.62 (33.25 to 45.27) |
The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.
| Score on a scale | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Change From Baseline of Mean Score Pain Severity (BPI-SF) | 0.52 ± 2.237 | -0.04 ± 2.408 |
The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 ("No pain", "No interference") to 10 ("Pain as bad as you can imagine", "Highest imaginable interference") numeric rating scale.
| Score on a scale | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| Change From Baseline of Mean Score Pain Interference (BPI-SF) | 0.95 ± 2.466 | 0.48 ± 2.868 |
Collected over From first dose up to 60 days post last dose of study therapy (Up to approximately 9 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 226/321 (70.4%) | 238/318 (74.8%) | 314/318 (98.7%) |
| Lenalidomide + Dexamethasone | 249/325 (76.6%) | 194/317 (61.2%) | 309/317 (97.5%) |
| Event | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| PneumoniaInfections and infestations | 56/318 | 40/317 |
| PyrexiaGeneral disorders | 25/318 | 17/317 |
| Disease progressionGeneral disorders | 15/318 | 10/317 |
| DiarrhoeaGastrointestinal disorders | 7/318 | 12/317 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 12/318 | 3/317 |
| AnaemiaBlood and lymphatic system disorders | 11/318 | 8/317 |
| Respiratory tract infectionInfections and infestations | 11/318 | 4/317 |
| Acute kidney injuryRenal and urinary disorders | 11/318 | 8/317 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 11/318 | 8/317 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 10/318 | 4/317 |
| Event | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 159/318 | 122/317 |
| FatigueGeneral disorders | 154/318 | 131/317 |
| NeutropeniaBlood and lymphatic system disorders | 114/318 | 137/317 |
| AnaemiaBlood and lymphatic system disorders | 135/318 | 118/317 |
| PyrexiaGeneral disorders | 121/318 | 74/317 |
| ConstipationGastrointestinal disorders | 115/318 | 89/317 |
| CoughRespiratory, thoracic and mediastinal disorders | 109/318 | 62/317 |
| Back painMusculoskeletal and connective tissue disorders | 105/318 | 97/317 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 99/318 | 85/317 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 98/318 | 63/317 |
Randomized: all participants randomized to any treatment group
| Age, Continuous(years) | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| Mean | 66.2 ± 9.34 | 65.3 ± 10.26 | 65.7 ± 9.81 |
| Age, Customized(Participants) | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| < 65 years old | 134 | 142 | 276 |
| >= 65 and < 75 years old | 119 | 122 | 241 |
| >= 75 years old | 68 | 61 | 129 |
| Sex: Female, Male(Participants) | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| Female | 129 | 132 | 261 |
| Male | 192 | 193 | 385 |
| Ethnicity (NIH/OMB)(Participants) | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 1 | 6 |
| Not Hispanic or Latino | 28 | 33 | 61 |
| Unknown or Not Reported | 288 | 291 | 579 |
| Race/Ethnicity, Customized(Participants) | Lenalidomide + Dexamethasone + Elotuzumab | Lenalidomide + Dexamethasone | Total |
|---|---|---|---|
| White | 264 | 280 | 544 |
| Black or African American | 13 | 10 | 23 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 33 | 31 | 64 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Other | 9 | 4 | 13 |
| Not Reported | 1 | 0 | 1 |
Showing the first 100 of 216 sites across 23 countries. Choose a country and city above to see the rest.
Ran from Jun 2011 to primary completion in Sep 2014, 38 months.
Results were first posted in Jan 2017, 2 years 4 months after primary completion.
Of 29 industry-sponsored phase 3 interventional studies under Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 69. This study's 38 months is below that.
Counting every sponsor, half of 62 studies reached it within 67 months; a quarter within 52 and three quarters within 106.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dexamethasone · Elotuzumab